हिंदी में पढ़ें
Income Tax Calculator
Personal Loan Calculator
Car Loan Calculator
Home Loan Calculator
MF Returns Calculator
Cipla is the TOP gainer on Nifty today; expert pegs price target between Rs 950-Rs 1000 going forward
Mon, Apr 12, 2021
Even as wider markets were down in a significant manner, Cipla share price today rose to Rs 915, up Rs 32 or 3.6%. Cipla share price has moved from Rs 837 to Rs 915 over the last week. Cipla share price topped the Nifty Gainers list on Friday as well. The stock is seeing good buying as revenues of the company is going to increase going forward on increasing Covid worries
Cipla is top GAINER on Nifty today, expert says BUY this share with price target of Rs 978
Fri, Apr 09, 2021
Cipla share price closed at Rs 883, up Rs 41 or 4.9%. Cipla moved from Rs 817 to Rs 883 in this week. Kotak Institutional Equities said that Lannett’s announcement of ANDA filing for Advair, a key pipeline product for Cipla, is in line with expectations and they see limited impact on Cipla’s Advair opportunity
Cipla Share price II Maintain BUY with Rs 1020 target says HDFC Securities
Tue, Feb 02, 2021
Cipla delivered yet another solid quarter, driven by healthy growth across businesses (India, CGA, Europe, API). EBITDA margin came ahead of expectation at 24% (+647bps YoY, +46bps QoQ), aided by tight control on costs. Cipla is tracking ahead of its initial cost saving guidance of Rs 4-5 bn for FY21 and expects to retain part of these benefits in the coming quarters. Its US business outlook remains strong as respiratory/ niche filings add longer-term growth visibility.
Pharma Sector Update: Torrent Pharma, Cipla, Lupin to Alkem Labs - HDFC Securities highlights
Thu, Jan 14, 2021
HDFC Securities see several growth catalysts across key markets and product categories (inhalers, biosimilars, complex injectables) playing out over the next 2-3 years for Indian pharma companies. The investments made over the last few years leave them well placed to capitalise on these opportunities. With cost bases pruned and operating leverage benefits, the sector is poised to grow at 21% earnings CAGR and witness ROCE improvement of 430bps to 15% over FY20- 23e.
Dr. Reddy's and Cipla are top picks of Jefferies in Pharma Sector
Tue, Jan 12, 2021
2020 was the best in recent years with the Pharma index outperforming Nifty by 45%. Jefferies remains positive on India Pharma driven by an average 13% EPS CAGR over FY21-23E. Exporters are set to gain on a stable pricing environment and complex product launches. Jefferies' key concern is the increasing role of price in driving growth in the India market and the emerging threat of e-pharmacies. Jefferies top large-cap picks are Dr. Reddy's and Cipla.
CLSA on Cipla, Glenmark, Cadila Healthcare, IPCA Labs and Lupin | What did not work for them and what did
Wed, Dec 16, 2020
CLSA highlights that it was a muted month for pharma companies as November sales disappoint for the Domestic Market. CLSA says it was a strong month for IPCA Labs; gains from integration of acquired brands for Dr Reddy. Falling active cases meant sales of Covid treatment drugs moderated for Glenmark / Cipla (+16%/-24% MoM). Glenmark saw the highest growth in its coverage in November, but excluding these products, its portfolio fell 1% YoY. Cipla’s core growth was a smaller 5.9% YoY.
Now, Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life are key stocks to watch
Tue, Dec 15, 2020
Among the top 30 companies Mylan clocked the highest growth of 144% for November followed by Glenmark Pharma(+11%), IPCA Labs (+10%) and Ajanta Pharma(+10%) clocking double digit growth while Novartis, Micro, Indoco Remedies, FDC & Mankind Pharma were impacted the most. With 144% growth for the month (sales of Rs 920 m), Mylan has been the standout performer for the month primarily aided by Rs 540 mn sales contribution from its COVID treatment drug, Desrem. Notably, Desrem was the second largest selling brand in IPM for Nov20. Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life were among some local listed players that clocked a single digit growth.
Derivatives summary for Traders: Cipla, Bata India, Hero Moto. HDFC Life key stocks to watch
Tue, Dec 15, 2020
The Nifty opened with a gain of 60 points on December 14, 2020, in line with strong cues from global markets. Thereafter, the Nifty went in negative zone due to profit booking at higher levels. Barring Nifty Auto and Reality indices, all other indices closed in the positive zone rising by 1-2%. In the afternoon, the Nifty managed to turn positive aided by buying at lower levels. Stocks like ONGC, LT, CIPLA, COALINDIA and IOC were top gainers that rose by 3-4%, while stocks like EICHERMOT, HEROMOTOCO, M&M, HDFCLIFE and TECHM were top losers that fell by 2-3%. The Nifty closed at around 13568 levels with a gain of 0.21%.
Cipla Share price: HDFC Securities says US growth to boost stock, raises target price to Rs 940
Mon, Dec 14, 2020
Cipla is licensed to sell volume-limited quantity after Mar 2022 and without volume-restriction after Jan 31, 2026 subject to product approval from the US FDA. While the details pertaining to launch date and market share are not disclosed, the opportunity can add an NPV of Rs4 0/share to target price in a base case scenario (assuming 5-10% market share, 30-50% price erosion between FY23-26). HDFC Securities increased their target price to Rs 940 to factor gRevlimid launch in FY23 and maintained BUY rating. Key catalysts are ramp-up in Albuterol, progress on IV Tramadol, limited competition launches in the US.
Jefferies highlights AstraZeneca Covid-19 vaccine data impact on India | Price, rivals to distribution, know it all
Tue, Nov 24, 2020
AstraZeneca vaccine will be able to vaccinate only 50% of the population by the end 2022, even if there are no supply/ funding constraints, according to Jefferies. A 70% efficacy with AstraZeneca would further delay the time to bring the Pandemic under control in India. High unmet demand leaves potential for other vaccine plays in India. Remdesivir could also see extended sales for Cipla and Cadila Healthcare.
Macquarie says Dr Reddy's, Cipla and Divi's Labs are top stock picks as Nifty Pharma trades at 12% premium to Nifty
Wed, Nov 11, 2020
Nifty Pharma now trades at a 12% premium to Nifty, this compares to a long-term average premium of 38%. Macquarie stays positive on India pharma companies. Dr Reddy's, Cipla and Divi's Labs are their top stock picks in large-cap pharma space while Syngene, Solara and Jubilant life are preferred mid-cap picks.
Dr Reddy's Labs, Cadila Healthcare, Alkem Labs, Cipla to IPCA Labs, all you need to know about Pharma Sector
Fri, Nov 06, 2020
CGSCIMB says they believe the domestic business’s strong recovery in growth should ensure healthy cash flows and better RocE. They initiate coverage on the Pharma sector with Overweight rating; add rating on Dr Reddy’s Labs, Cadila Healthcare, Alkem Labs, Cipla, IPCA Labs, Natco Pharma, Ajanta Pharma, Indoco Remedies and Hold rating on Alembic Pharma, Torrent Pharma.
Diwali 2020 Picks: Infosys, ICICI Bank, Britannia to Cipla are stocks to buy, says Kotak Securities
Thu, Nov 05, 2020
Benchmark Nifty has rebounded sharply after hitting the levels of 7510 in the month of March 2020. The index is in the third leg of a major corrective pattern. It is correcting after hitting the crucial and psychological mark of 12000. Until the market is above the level of 10800 (previous significant bottom), Nifty would keep rallying. Below 10800 levels Nifty would lose its momentum and may even fall to 10300 levels. On the decisive crossing of 12400 levels would lift the Nifty to 13300 levels.
CLSA Maintains Buy Rating on Sun Pharma, Cadila Healthcare, Torrent Pharma and Abbott India; Outperform on Cipla
Fri, Oct 09, 2020
CLSA believes that fundamentals for the pharma sector in 2020 are much healthier than even in 2015.
Nikhil Chopra Joins JB Chemicals as CEO, Vikas Gupta to head prescription biz at Cipla
Mon, Oct 05, 2020
In a significant move today that has wide-ranging ramifications for the segment, ex-Cipla India Business CEO Nikhil Chopra has joined JB Chemicals as a Whole Time Director and CEO today for a tenure of 5 years.
Top Stocks to Buy Today: SBI, Indian Bank, IndusInd Bank to Tech Mahindra, here are 20 money-makers for you
Thu, Aug 13, 2020
Top Stocks to Buy Today: Zee Business Fast Money team has come out with 20 top shares that can help traders mint money at a faster rate.
Cipla likely to start clinical trials of two respiratory products in the US: Kedar Upadhye, Global CFO
Wed, Aug 12, 2020
Kedar Upadhye, Global Chief Financial Officer, Cipla Limited, talks about Albuterol, the US business, product pipelines, margins and Goa facility among others during a candid chat with Swati Khandelwal, Zee Business.
Stock Markets Today: Sensex, Nifty end on a positive note; Cipla, Mahindra in gainers list
Mon, Aug 10, 2020
Stock markets today ended the day in the green. While the BSE Sensex was trading at 38,182 at the close, up by over 0.3 per cent or 141 points, the broader market NSE Nifty 50 was trading 11,274.70, up by over 0.5 per cent 60 points around this time from the previous close on Friday
Stocks in Focus on August 7: Banks, HPCL to Jubilant FoodWorks; here are expected newsmakers of the day
Fri, Aug 07, 2020
Stocks in Focus on August 7: HPCL, Jubilant FoodWorks, Pidilite Industries, Adani Enterprises, Torrent Power, etc. are expected newsmakers throughout the intraday trade session.
Coronavirus Drug: Cipla gets DCGI nod to sell Favipiravir under brand 'Ciplenza'
Sat, Jul 25, 2020
Drug maker Cipla Ltd. on Friday said it has received regulatory approval from Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza to treat mild to moderate Covid-19 patients.